

Nicholas J Clemons

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2052159/publications.pdf>

Version: 2024-02-01

46
papers

1,931
citations

394421

19
h-index

254184

43
g-index

54
all docs

54
docs citations

54
times ranked

3111
citing authors

#	ARTICLE	IF	CITATIONS
1	C5b-9 Membrane Attack Complex Formation and Extracellular Vesicle Shedding in Barrett's Esophagus and Esophageal Adenocarcinoma. <i>Frontiers in Immunology</i> , 2022, 13, 842023.	4.8	4
2	Elevation of fatty acid desaturase Δ 2 in esophageal adenocarcinoma increases polyunsaturated lipids and may exacerbate bile acid-induced DNA damage. <i>Clinical and Translational Medicine</i> , 2022, 12, e810.	4.0	6
3	Epithelial de-differentiation triggered by co-ordinate epigenetic inactivation of the EHF and CDX1 transcription factors drives colorectal cancer progression. <i>Cell Death and Differentiation</i> , 2022, 29, 2288-2302.	11.2	6
4	Multiparametric High-Content Cell Painting Identifies Copper Ionophores as Selective Modulators of Esophageal Cancer Phenotypes. <i>ACS Chemical Biology</i> , 2022, 17, 1876-1889.	3.4	11
5	Loss of SMAD4 Is Sufficient to Promote Tumorigenesis in a Model of Dysplastic Barrett's Esophagus. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2021, 12, 689-713.	4.5	11
6	Transketolase regulates sensitivity to APR-246 in p53-null cells independently of oxidative stress modulation. <i>Scientific Reports</i> , 2021, 11, 4480.	3.3	5
7	The TIM22 complex mediates the import of sideroflexins and is required for efficient mitochondrial one-carbon metabolism. <i>Molecular Biology of the Cell</i> , 2021, 32, 475-491.	2.1	19
8	Mutant p53 Mediates Sensitivity to Cancer Treatment Agents in Oesophageal Adenocarcinoma Associated with MicroRNA and SLC7A11 Expression. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5547.	4.1	9
9	HOXA13 in etiology and oncogenic potential of Barrett's esophagus. <i>Nature Communications</i> , 2021, 12, 3354.	12.8	5
10	Opportunities for Ferroptosis in Cancer Therapy. <i>Antioxidants</i> , 2021, 10, 986.	5.1	15
11	SLC7A11 Is a Superior Determinant of APR-246 (Eprentapopt) Response than TP53 Mutation Status. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1858-1867.	4.1	24
12	Mutant p53-reactivating compound APR-246 synergizes with asparaginase in inducing growth suppression in acute lymphoblastic leukemia cells. <i>Cell Death and Disease</i> , 2021, 12, 709.	6.3	11
13	Trapping Colorectal Cancer Into a Dead-end. <i>Gastroenterology</i> , 2021, 161, 33-35.	1.3	0
14	732 TUMOR INFILTRATING NEUTROPHILS ARE A POOR PROGNOSTIC MARKER FOR ESOPHAGEAL CANCER PATIENTS RECEIVING NEOADJUVANT CHEMORADIOTHERAPY. <i>Ecological Management and Restoration</i> , 2021, 34, .	0.4	0
15	814 SMAD4 AS A POTENTIAL GATEKEEPER FOR GENOMIC INSTABILITY AND MTOR-MEDIATED TUMORIGENESIS IN ESOPHAGEAL ADENOCARCINOMA. <i>Ecological Management and Restoration</i> , 2021, 34, .	0.4	0
16	A thiol-bound drug reservoir enhances APR-246-induced mutant p53 tumor cell death. <i>EMBO Molecular Medicine</i> , 2021, 13, e10852.	6.9	28
17	Cyclooxygenases and Prostaglandins in Tumor Immunology and Microenvironment of Gastrointestinal Cancer. <i>Gastroenterology</i> , 2021, 161, 1813-1829.	1.3	60
18	GRB7 is an oncogenic driver and potential therapeutic target in oesophageal adenocarcinoma. <i>Journal of Pathology</i> , 2020, 252, 317-329.	4.5	8

#	ARTICLE	IF	CITATIONS
19	Function of hTim8a in complex IV assembly in neuronal cells provides insight into pathomechanism underlying Mohr-Tranebjerg syndrome. <i>ELife</i> , 2019, 8, .	6.0	34
20	Bridging the molecular divide: alcohol-induced downregulation of PAX9 and tumour development. <i>Journal of Pathology</i> , 2018, 244, 386-388.	4.5	6
21	Preclinical models for the study of Barrett's carcinogenesis. <i>Annals of the New York Academy of Sciences</i> , 2018, 1434, 139-148.	3.8	3
22	TGF-beta signaling and its targeted therapy in gastrointestinal cancers. <i>Discovery Medicine</i> , 2018, 26, 103-112.	0.5	8
23	The prognostic value of TP53 mutations in oesophageal adenocarcinoma: a systematic review and meta-analysis. <i>Gut</i> , 2017, 66, 399-410.	12.1	31
24	Inhibiting the system x _C ⁺ /glutathione axis selectively targets cancers with mutant-p53 accumulation. <i>Nature Communications</i> , 2017, 8, 14844.	12.8	229
25	Inhibiting system x _C ⁺ and glutathione biosynthesis – a potential Achilles' heel in mutant-p53 cancers. <i>Molecular and Cellular Oncology</i> , 2017, 4, e1344757.	0.7	12
26	The Genetics of Barrett's Esophagus: A Familial and Population-Based Perspective. <i>Digestive Diseases and Sciences</i> , 2016, 61, 1826-1834.	2.3	7
27	Intramuscular Transplantation Improves Engraftment Rates for Esophageal Patient-Derived Tumor Xenografts. <i>Annals of Surgical Oncology</i> , 2016, 23, 305-311.	1.5	23
28	Novel metastatic models of esophageal adenocarcinoma derived from FLO-1 cells highlight the importance of E-cadherin in cancer metastasis. <i>Oncotarget</i> , 2016, 7, 83342-83358.	1.8	14
29	Cancer-associated fibroblasts predict poor outcome and promote periostin-dependent invasion in oesophageal adenocarcinoma. <i>Journal of Pathology</i> , 2015, 235, 466-477.	4.5	154
30	APR-246 potently inhibits tumour growth and overcomes chemoresistance in preclinical models of oesophageal adenocarcinoma. <i>Gut</i> , 2015, 64, 1506-1516.	12.1	84
31	Characterization of a Novel Tumorigenic Esophageal Adenocarcinoma Cell Line: OANC1. <i>Digestive Diseases and Sciences</i> , 2014, 59, 78-88.	2.3	10
32	Hedgehog signaling regulates FOXA2 in esophageal embryogenesis and Barrett's metaplasia. <i>Journal of Clinical Investigation</i> , 2014, 124, 3767-3780.	8.2	81
33	Advances in understanding the pathogenesis of Barrett's esophagus. <i>Discovery Medicine</i> , 2014, 17, 7-14.	0.5	12
34	Molecular changes in the phosphatidylinositide 3-kinase (PI3K) pathway are common in gastric cancer. <i>Journal of Surgical Oncology</i> , 2013, 108, 113-120.	1.7	11
35	Barrett's esophagus: cancer and molecular biology. <i>Annals of the New York Academy of Sciences</i> , 2013, 1300, 296-314.	3.8	24
36	Signaling pathways in the molecular pathogenesis of adenocarcinomas of the esophagus and gastroesophageal junction. <i>Cancer Biology and Therapy</i> , 2013, 14, 782-795.	3.4	40

#	ARTICLE	IF	CITATIONS
37	Sox9 drives columnar differentiation of esophageal squamous epithelium: a possible role in the pathogenesis of Barrett's esophagus. <i>American Journal of Physiology - Renal Physiology</i> , 2012, 303, G1335-G1346.	3.4	50
38	Mutations in the selenocysteine insertion sequenceâ€“binding protein 2 gene lead to a multisystem selenoprotein deficiency disorder in humans. <i>Journal of Clinical Investigation</i> , 2010, 120, 4220-4235.	8.2	268
39	Nitric oxide-mediated invasion in Barrett's high-grade dysplasia and adenocarcinoma. <i>Carcinogenesis</i> , 2010, 31, 1669-1675.	2.8	23
40	Stromal genes discriminate preinvasive from invasive disease, predict outcome, and highlight inflammatory pathways in digestive cancers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 2177-2182.	7.1	143
41	Aberrant Epithelialâ€“Mesenchymal Hedgehog Signaling Characterizes Barrett's Metaplasia. <i>Gastroenterology</i> , 2010, 138, 1810-1822.e2.	1.3	156
42	Nitric Oxide and Acid Induce Double-Strand DNA Breaks in Barrett's Esophagus Carcinogenesis via Distinct Mechanisms. <i>Gastroenterology</i> , 2007, 133, 1198-1209.	1.3	94
43	TRAIL-induced apoptosis is enhanced by heat shock protein 70 expression. <i>Cell Stress and Chaperones</i> , 2006, 11, 343.	2.9	14
44	Hsp72 Inhibits Fas-mediated Apoptosis Upstream of the Mitochondria in Type II Cells. <i>Journal of Biological Chemistry</i> , 2005, 280, 9005-9012.	3.4	44
45	Hsp72 Inhibits Apoptosis Upstream of the Mitochondria and Not through Interactions with Apaf-1. <i>Journal of Biological Chemistry</i> , 2004, 279, 51490-51499.	3.4	118
46	Pathogenesis of Barrett's Esophagus. , 0, , 27-37.		0